Skip to main content

Table 3 Symptoms at 6 months in the included patients

From: The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study

 

Respondersa

(n = 115)

New disability

Yes

(n = 42)

No

(n = 66)

p value

Any symptom—no. (%)

82 (71.3)

34 (81.0)

46 (69.7)

0.261

Number of symptoms—no. (%)

   

0.001

1

23 (20.0)

3 (7.1)

20 (30.3)

 

2

9 (7.8)

3 (7.1)

6 (9.1)

 

 ≥ 3

50 (43.5)

28 (66.7)

20 (30.3)

 

Symptoms—no. (%)

    

Shortness of breath

40 (34.8)

26 (61.9)

14 (21.2)

 < 0.001

Loss of strength

25 (21.7)

19 (45.2)

6 (9.1)

 < 0.001

Fatigue

22 (19.1)

11 (26.2)

10 (15.2)

0.213

Persistent cough

16 (13.9)

10 (23.8)

6 (9.1)

0.051

Loss of taste

14 (12.2)

9 (21.4)

5 (7.6)

0.044

Loss of smell

14 (12.2)

9 (21.4)

4 (6.1)

0.030

Headache

12 (10.4)

7 (16.7)

3 (4.5)

0.045

Persistent chest pain

8 (7.0)

5 (11.9)

2 (3.0)

0.107

Palpitations

8 (7.0)

4 (9.5)

4 (6.1)

0.709

Myalgia/arthralgia

8 (7.0)

3 (7.1)

5 (7.6)

0.999

Loss of sensation

7 (6.1)

4 (9.5)

3 (4.5)

0.427

Hair loss

6 (5.2)

3 (7.1)

3 (4.5)

0.676

Weight loss

6 (5.2)

3 (7.1)

3 (4.5)

0.676

Anxiety

5 (4.3)

3 (7.1)

2 (3.0)

0.375

Other

28 (24.3)

15 (35.7)

12 (18.2)

0.067

  1. Data are no (%). Percentages may not total 100 because of rounding
  2. aThe follow-up cohort comprises patients who were contacted successfully at 6 months. However, data may be missing for some outcomes depending on the willingness of the patient to answer all questions